How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

Related Videos